Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Pfizer to Enjoy Monopoly in Asacol Generic Market until December
September 14, 2015
- Fluvoxamine Shows Significant Difference against Placebo for Pediatric Obsessive-Compulsive Disorder in PIII Study: Meiji Seika Pharma
September 14, 2015
- FDA Grants Priority Review Status to Multiple Myeloma Drug Ixazomib: Takeda
September 11, 2015
- Ethical Drug Sales Up 6.5% in July: Crecon Report
September 10, 2015
- MTPC, Biogen Partner Up on Imusera Successor
September 10, 2015
- Sanwa Kagaku, Ube to Codevelop Pruritus Treatment
September 10, 2015
- Clinical Study of JACE for Giant Pigmented Nevus Completed: J-TEC
September 9, 2015
- Sanofi Rolls Out Plaquenil, Lantus XR in Japan
September 8, 2015
- FDA Grants Breakthrough Therapy Designation to Hemophilia A Treatment ACE910: Chugai
September 7, 2015
- MSD Paid 13 Billion Yen to Doctors, Medical Institutions in 2014
September 3, 2015
- Merck Serono Japan Wants to Be Leader in Oncology, Fertility: President
September 3, 2015
- Towa to Improve Production Efficiencies and Facilities at Yamagata Plant in Response to Rising Generic Demand
September 3, 2015
- AZ, Daiichi Sankyo Team Up for Development, Commercialization of Nasal Flu Vaccine in Japan
September 3, 2015
- GSK Adjusts Shipments of Hepatitis B Treatment Tenozet Due to Disaster-Stricken Plant Following Tianjin Explosion in China
September 2, 2015
- Pfizer Japan Slapped with Biz Improvement Order over ADR Reporting
September 2, 2015
- Sanofi Names Former Keio University Professor Yuji Sato as R&D Head
September 2, 2015
- Eisai to Develop Insomnia Treatment Lemborexant with Purdue Pharma of US
September 2, 2015
- Genzyme Japan Launches Oral Gaucher’s Disease Treatment Cerdelga
September 2, 2015
- Harvoni, Yervoy, Other New Drugs Hit Japan Market
September 1, 2015
- Baxalta Japan Aims for 6-8% Annual Growth by 2020: President Kawamoto
September 1, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…